nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefdinir—MPO—Carboplatin—testicular cancer	0.3	0.396	CbGbCtD
Cefdinir—MPO—Cisplatin—testicular cancer	0.256	0.339	CbGbCtD
Cefdinir—SLC22A5—Dactinomycin—testicular cancer	0.2	0.265	CbGbCtD
Cefdinir—Abdominal pain—Vinblastine—testicular cancer	0.000412	0.00169	CcSEcCtD
Cefdinir—Asthenia—Chlorambucil—testicular cancer	0.000408	0.00167	CcSEcCtD
Cefdinir—Vaginal infection—Doxorubicin—testicular cancer	0.000408	0.00167	CcSEcCtD
Cefdinir—Aplastic anaemia—Doxorubicin—testicular cancer	0.000405	0.00166	CcSEcCtD
Cefdinir—Hepatic failure—Methotrexate—testicular cancer	0.000403	0.00165	CcSEcCtD
Cefdinir—Pruritus—Chlorambucil—testicular cancer	0.000402	0.00165	CcSEcCtD
Cefdinir—Thrombocytopenia—Dactinomycin—testicular cancer	0.000402	0.00165	CcSEcCtD
Cefdinir—Convulsion—Ifosfamide—testicular cancer	0.000399	0.00164	CcSEcCtD
Cefdinir—Hypertension—Ifosfamide—testicular cancer	0.000398	0.00163	CcSEcCtD
Cefdinir—Erythema multiforme—Etoposide—testicular cancer	0.000395	0.00162	CcSEcCtD
Cefdinir—Rash maculo-papular—Doxorubicin—testicular cancer	0.000392	0.00161	CcSEcCtD
Cefdinir—Chest pain—Ifosfamide—testicular cancer	0.000392	0.00161	CcSEcCtD
Cefdinir—Renal failure acute—Methotrexate—testicular cancer	0.000392	0.00161	CcSEcCtD
Cefdinir—Flatulence—Cisplatin—testicular cancer	0.000391	0.0016	CcSEcCtD
Cefdinir—Anorexia—Dactinomycin—testicular cancer	0.000391	0.0016	CcSEcCtD
Cefdinir—Diarrhoea—Chlorambucil—testicular cancer	0.000389	0.00159	CcSEcCtD
Cefdinir—Hepatic function abnormal—Epirubicin—testicular cancer	0.000388	0.00159	CcSEcCtD
Cefdinir—Hypersensitivity—Vinblastine—testicular cancer	0.000384	0.00157	CcSEcCtD
Cefdinir—Dermatitis exfoliative—Methotrexate—testicular cancer	0.000384	0.00157	CcSEcCtD
Cefdinir—Decreased appetite—Bleomycin—testicular cancer	0.000382	0.00157	CcSEcCtD
Cefdinir—Hepatic failure—Epirubicin—testicular cancer	0.000377	0.00154	CcSEcCtD
Cefdinir—Anaphylactic shock—Ifosfamide—testicular cancer	0.000376	0.00154	CcSEcCtD
Cefdinir—Asthenia—Vinblastine—testicular cancer	0.000374	0.00153	CcSEcCtD
Cefdinir—Thrombocytopenia—Ifosfamide—testicular cancer	0.000368	0.00151	CcSEcCtD
Cefdinir—Renal failure acute—Epirubicin—testicular cancer	0.000367	0.0015	CcSEcCtD
Cefdinir—Vomiting—Chlorambucil—testicular cancer	0.000361	0.00148	CcSEcCtD
Cefdinir—Dermatitis exfoliative—Epirubicin—testicular cancer	0.000359	0.00147	CcSEcCtD
Cefdinir—Hepatic function abnormal—Doxorubicin—testicular cancer	0.000359	0.00147	CcSEcCtD
Cefdinir—Anorexia—Ifosfamide—testicular cancer	0.000358	0.00147	CcSEcCtD
Cefdinir—Decreased appetite—Dactinomycin—testicular cancer	0.000357	0.00146	CcSEcCtD
Cefdinir—Diarrhoea—Vinblastine—testicular cancer	0.000356	0.00146	CcSEcCtD
Cefdinir—Renal impairment—Epirubicin—testicular cancer	0.000356	0.00146	CcSEcCtD
Cefdinir—Leukopenia—Cisplatin—testicular cancer	0.000356	0.00146	CcSEcCtD
Cefdinir—Purpura—Epirubicin—testicular cancer	0.000351	0.00144	CcSEcCtD
Cefdinir—Hepatic failure—Doxorubicin—testicular cancer	0.000349	0.00143	CcSEcCtD
Cefdinir—Body temperature increased—Bleomycin—testicular cancer	0.000348	0.00143	CcSEcCtD
Cefdinir—Cardiac failure—Epirubicin—testicular cancer	0.000347	0.00142	CcSEcCtD
Cefdinir—Dizziness—Vinblastine—testicular cancer	0.000344	0.00141	CcSEcCtD
Cefdinir—Convulsion—Cisplatin—testicular cancer	0.000344	0.00141	CcSEcCtD
Cefdinir—Renal failure acute—Doxorubicin—testicular cancer	0.000339	0.00139	CcSEcCtD
Cefdinir—Nausea—Chlorambucil—testicular cancer	0.000338	0.00138	CcSEcCtD
Cefdinir—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000336	0.00137	CcSEcCtD
Cefdinir—Somnolence—Ifosfamide—testicular cancer	0.000334	0.00137	CcSEcCtD
Cefdinir—Dermatitis exfoliative—Doxorubicin—testicular cancer	0.000332	0.00136	CcSEcCtD
Cefdinir—Vomiting—Vinblastine—testicular cancer	0.000331	0.00136	CcSEcCtD
Cefdinir—Renal impairment—Doxorubicin—testicular cancer	0.000329	0.00135	CcSEcCtD
Cefdinir—Decreased appetite—Ifosfamide—testicular cancer	0.000327	0.00134	CcSEcCtD
Cefdinir—Headache—Vinblastine—testicular cancer	0.000326	0.00134	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000326	0.00134	CcSEcCtD
Cefdinir—Leukopenia—Etoposide—testicular cancer	0.000326	0.00133	CcSEcCtD
Cefdinir—Purpura—Doxorubicin—testicular cancer	0.000325	0.00133	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000325	0.00133	CcSEcCtD
Cefdinir—Abdominal pain—Dactinomycin—testicular cancer	0.000324	0.00133	CcSEcCtD
Cefdinir—Body temperature increased—Dactinomycin—testicular cancer	0.000324	0.00133	CcSEcCtD
Cefdinir—Anaphylactic shock—Cisplatin—testicular cancer	0.000324	0.00133	CcSEcCtD
Cefdinir—Hypersensitivity—Bleomycin—testicular cancer	0.000324	0.00133	CcSEcCtD
Cefdinir—Constipation—Ifosfamide—testicular cancer	0.000322	0.00132	CcSEcCtD
Cefdinir—Cardiac failure—Doxorubicin—testicular cancer	0.000321	0.00132	CcSEcCtD
Cefdinir—Loss of consciousness—Etoposide—testicular cancer	0.00032	0.00131	CcSEcCtD
Cefdinir—Thrombocytopenia—Cisplatin—testicular cancer	0.000317	0.0013	CcSEcCtD
Cefdinir—Asthenia—Bleomycin—testicular cancer	0.000316	0.00129	CcSEcCtD
Cefdinir—Convulsion—Etoposide—testicular cancer	0.000315	0.00129	CcSEcCtD
Cefdinir—Hypertension—Etoposide—testicular cancer	0.000314	0.00129	CcSEcCtD
Cefdinir—Asthma—Methotrexate—testicular cancer	0.000313	0.00128	CcSEcCtD
Cefdinir—Pruritus—Bleomycin—testicular cancer	0.000311	0.00128	CcSEcCtD
Cefdinir—Chest pain—Etoposide—testicular cancer	0.00031	0.00127	CcSEcCtD
Cefdinir—Nausea—Vinblastine—testicular cancer	0.000309	0.00127	CcSEcCtD
Cefdinir—Anorexia—Cisplatin—testicular cancer	0.000309	0.00127	CcSEcCtD
Cefdinir—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000307	0.00126	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000305	0.00125	CcSEcCtD
Cefdinir—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000305	0.00125	CcSEcCtD
Cefdinir—Hypersensitivity—Dactinomycin—testicular cancer	0.000302	0.00124	CcSEcCtD
Cefdinir—Body temperature increased—Ifosfamide—testicular cancer	0.000297	0.00122	CcSEcCtD
Cefdinir—Abdominal pain—Ifosfamide—testicular cancer	0.000297	0.00122	CcSEcCtD
Cefdinir—Pancytopenia—Methotrexate—testicular cancer	0.000297	0.00122	CcSEcCtD
Cefdinir—Anaphylactic shock—Etoposide—testicular cancer	0.000297	0.00122	CcSEcCtD
Cefdinir—Asthenia—Dactinomycin—testicular cancer	0.000294	0.00121	CcSEcCtD
Cefdinir—Asthma—Epirubicin—testicular cancer	0.000293	0.0012	CcSEcCtD
Cefdinir—Neutropenia—Methotrexate—testicular cancer	0.000293	0.0012	CcSEcCtD
Cefdinir—Thrombocytopenia—Etoposide—testicular cancer	0.000291	0.00119	CcSEcCtD
Cefdinir—Anorexia—Etoposide—testicular cancer	0.000283	0.00116	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000282	0.00116	CcSEcCtD
Cefdinir—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000282	0.00116	CcSEcCtD
Cefdinir—Decreased appetite—Cisplatin—testicular cancer	0.000282	0.00115	CcSEcCtD
Cefdinir—Diarrhoea—Dactinomycin—testicular cancer	0.000281	0.00115	CcSEcCtD
Cefdinir—Pneumonia—Methotrexate—testicular cancer	0.000281	0.00115	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00028	0.00115	CcSEcCtD
Cefdinir—Vomiting—Bleomycin—testicular cancer	0.00028	0.00115	CcSEcCtD
Cefdinir—Pancytopenia—Epirubicin—testicular cancer	0.000278	0.00114	CcSEcCtD
Cefdinir—Rash—Bleomycin—testicular cancer	0.000277	0.00114	CcSEcCtD
Cefdinir—Dermatitis—Bleomycin—testicular cancer	0.000277	0.00114	CcSEcCtD
Cefdinir—Hypersensitivity—Ifosfamide—testicular cancer	0.000277	0.00114	CcSEcCtD
Cefdinir—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000277	0.00113	CcSEcCtD
Cefdinir—Renal failure—Methotrexate—testicular cancer	0.000274	0.00112	CcSEcCtD
Cefdinir—Neutropenia—Epirubicin—testicular cancer	0.000274	0.00112	CcSEcCtD
Cefdinir—Stomatitis—Methotrexate—testicular cancer	0.000272	0.00111	CcSEcCtD
Cefdinir—Conjunctivitis—Methotrexate—testicular cancer	0.000271	0.00111	CcSEcCtD
Cefdinir—Asthma—Doxorubicin—testicular cancer	0.000271	0.00111	CcSEcCtD
Cefdinir—Asthenia—Ifosfamide—testicular cancer	0.00027	0.00111	CcSEcCtD
Cefdinir—Pruritus—Ifosfamide—testicular cancer	0.000266	0.00109	CcSEcCtD
Cefdinir—Haematuria—Methotrexate—testicular cancer	0.000266	0.00109	CcSEcCtD
Cefdinir—Somnolence—Etoposide—testicular cancer	0.000264	0.00108	CcSEcCtD
Cefdinir—Pneumonia—Epirubicin—testicular cancer	0.000263	0.00108	CcSEcCtD
Cefdinir—Nausea—Bleomycin—testicular cancer	0.000261	0.00107	CcSEcCtD
Cefdinir—Vomiting—Dactinomycin—testicular cancer	0.000261	0.00107	CcSEcCtD
Cefdinir—Agranulocytosis—Methotrexate—testicular cancer	0.00026	0.00107	CcSEcCtD
Cefdinir—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000259	0.00106	CcSEcCtD
Cefdinir—Rash—Dactinomycin—testicular cancer	0.000259	0.00106	CcSEcCtD
Cefdinir—Decreased appetite—Etoposide—testicular cancer	0.000258	0.00106	CcSEcCtD
Cefdinir—Diarrhoea—Ifosfamide—testicular cancer	0.000257	0.00105	CcSEcCtD
Cefdinir—Pancytopenia—Doxorubicin—testicular cancer	0.000257	0.00105	CcSEcCtD
Cefdinir—Renal failure—Epirubicin—testicular cancer	0.000257	0.00105	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Etoposide—testicular cancer	0.000256	0.00105	CcSEcCtD
Cefdinir—Body temperature increased—Cisplatin—testicular cancer	0.000256	0.00105	CcSEcCtD
Cefdinir—Stomatitis—Epirubicin—testicular cancer	0.000254	0.00104	CcSEcCtD
Cefdinir—Jaundice—Epirubicin—testicular cancer	0.000254	0.00104	CcSEcCtD
Cefdinir—Constipation—Etoposide—testicular cancer	0.000254	0.00104	CcSEcCtD
Cefdinir—Conjunctivitis—Epirubicin—testicular cancer	0.000254	0.00104	CcSEcCtD
Cefdinir—Neutropenia—Doxorubicin—testicular cancer	0.000253	0.00104	CcSEcCtD
Cefdinir—Haemoglobin—Methotrexate—testicular cancer	0.000252	0.00103	CcSEcCtD
Cefdinir—Haemorrhage—Methotrexate—testicular cancer	0.00025	0.00103	CcSEcCtD
Cefdinir—Haematuria—Epirubicin—testicular cancer	0.000249	0.00102	CcSEcCtD
Cefdinir—Dizziness—Ifosfamide—testicular cancer	0.000249	0.00102	CcSEcCtD
Cefdinir—Nausea—Dactinomycin—testicular cancer	0.000244	0.000999	CcSEcCtD
Cefdinir—Agranulocytosis—Epirubicin—testicular cancer	0.000244	0.000998	CcSEcCtD
Cefdinir—Pneumonia—Doxorubicin—testicular cancer	0.000243	0.000995	CcSEcCtD
Cefdinir—Gastrointestinal pain—Etoposide—testicular cancer	0.000243	0.000995	CcSEcCtD
Cefdinir—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000239	0.000981	CcSEcCtD
Cefdinir—Vomiting—Ifosfamide—testicular cancer	0.000239	0.00098	CcSEcCtD
Cefdinir—Hypersensitivity—Cisplatin—testicular cancer	0.000239	0.000979	CcSEcCtD
Cefdinir—Renal failure—Doxorubicin—testicular cancer	0.000237	0.000973	CcSEcCtD
Cefdinir—Rash—Ifosfamide—testicular cancer	0.000237	0.000971	CcSEcCtD
Cefdinir—Dermatitis—Ifosfamide—testicular cancer	0.000237	0.00097	CcSEcCtD
Cefdinir—Erythema multiforme—Methotrexate—testicular cancer	0.000237	0.00097	CcSEcCtD
Cefdinir—Haemoglobin—Epirubicin—testicular cancer	0.000236	0.000965	CcSEcCtD
Cefdinir—Stomatitis—Doxorubicin—testicular cancer	0.000235	0.000965	CcSEcCtD
Cefdinir—Jaundice—Doxorubicin—testicular cancer	0.000235	0.000965	CcSEcCtD
Cefdinir—Body temperature increased—Etoposide—testicular cancer	0.000235	0.000962	CcSEcCtD
Cefdinir—Abdominal pain—Etoposide—testicular cancer	0.000235	0.000962	CcSEcCtD
Cefdinir—Conjunctivitis—Doxorubicin—testicular cancer	0.000235	0.000962	CcSEcCtD
Cefdinir—Haemorrhage—Epirubicin—testicular cancer	0.000234	0.00096	CcSEcCtD
Cefdinir—Asthenia—Cisplatin—testicular cancer	0.000233	0.000953	CcSEcCtD
Cefdinir—Haematuria—Doxorubicin—testicular cancer	0.00023	0.000943	CcSEcCtD
Cefdinir—Agranulocytosis—Doxorubicin—testicular cancer	0.000225	0.000923	CcSEcCtD
Cefdinir—Nausea—Ifosfamide—testicular cancer	0.000223	0.000915	CcSEcCtD
Cefdinir—Diarrhoea—Cisplatin—testicular cancer	0.000222	0.000909	CcSEcCtD
Cefdinir—Erythema multiforme—Epirubicin—testicular cancer	0.000222	0.000908	CcSEcCtD
Cefdinir—Hypersensitivity—Etoposide—testicular cancer	0.000219	0.000896	CcSEcCtD
Cefdinir—Haemoglobin—Doxorubicin—testicular cancer	0.000218	0.000893	CcSEcCtD
Cefdinir—Haemorrhage—Doxorubicin—testicular cancer	0.000217	0.000888	CcSEcCtD
Cefdinir—Asthenia—Etoposide—testicular cancer	0.000213	0.000873	CcSEcCtD
Cefdinir—Pruritus—Etoposide—testicular cancer	0.00021	0.000861	CcSEcCtD
Cefdinir—Vomiting—Cisplatin—testicular cancer	0.000206	0.000844	CcSEcCtD
Cefdinir—Erythema multiforme—Doxorubicin—testicular cancer	0.000205	0.00084	CcSEcCtD
Cefdinir—Rash—Cisplatin—testicular cancer	0.000204	0.000837	CcSEcCtD
Cefdinir—Dermatitis—Cisplatin—testicular cancer	0.000204	0.000837	CcSEcCtD
Cefdinir—Diarrhoea—Etoposide—testicular cancer	0.000203	0.000833	CcSEcCtD
Cefdinir—Flatulence—Epirubicin—testicular cancer	0.000201	0.000824	CcSEcCtD
Cefdinir—Dizziness—Etoposide—testicular cancer	0.000196	0.000805	CcSEcCtD
Cefdinir—Leukopenia—Methotrexate—testicular cancer	0.000195	0.000799	CcSEcCtD
Cefdinir—Nausea—Cisplatin—testicular cancer	0.000193	0.000789	CcSEcCtD
Cefdinir—Convulsion—Methotrexate—testicular cancer	0.000189	0.000774	CcSEcCtD
Cefdinir—Vomiting—Etoposide—testicular cancer	0.000189	0.000774	CcSEcCtD
Cefdinir—Agitation—Epirubicin—testicular cancer	0.000187	0.000768	CcSEcCtD
Cefdinir—Rash—Etoposide—testicular cancer	0.000187	0.000767	CcSEcCtD
Cefdinir—Dermatitis—Etoposide—testicular cancer	0.000187	0.000766	CcSEcCtD
Cefdinir—Headache—Etoposide—testicular cancer	0.000186	0.000762	CcSEcCtD
Cefdinir—Flatulence—Doxorubicin—testicular cancer	0.000186	0.000762	CcSEcCtD
Cefdinir—Chest pain—Methotrexate—testicular cancer	0.000186	0.00076	CcSEcCtD
Cefdinir—Leukopenia—Epirubicin—testicular cancer	0.000183	0.000748	CcSEcCtD
Cefdinir—Loss of consciousness—Epirubicin—testicular cancer	0.000179	0.000735	CcSEcCtD
Cefdinir—Anaphylactic shock—Methotrexate—testicular cancer	0.000178	0.000729	CcSEcCtD
Cefdinir—Convulsion—Epirubicin—testicular cancer	0.000177	0.000724	CcSEcCtD
Cefdinir—Nausea—Etoposide—testicular cancer	0.000176	0.000723	CcSEcCtD
Cefdinir—Hypertension—Epirubicin—testicular cancer	0.000176	0.000722	CcSEcCtD
Cefdinir—Thrombocytopenia—Methotrexate—testicular cancer	0.000174	0.000714	CcSEcCtD
Cefdinir—Chest pain—Epirubicin—testicular cancer	0.000174	0.000712	CcSEcCtD
Cefdinir—Agitation—Doxorubicin—testicular cancer	0.000173	0.000711	CcSEcCtD
Cefdinir—Dry mouth—Epirubicin—testicular cancer	0.00017	0.000696	CcSEcCtD
Cefdinir—Anorexia—Methotrexate—testicular cancer	0.00017	0.000695	CcSEcCtD
Cefdinir—Leukopenia—Doxorubicin—testicular cancer	0.000169	0.000692	CcSEcCtD
Cefdinir—Anaphylactic shock—Epirubicin—testicular cancer	0.000166	0.000682	CcSEcCtD
Cefdinir—Loss of consciousness—Doxorubicin—testicular cancer	0.000166	0.00068	CcSEcCtD
Cefdinir—Shock—Epirubicin—testicular cancer	0.000164	0.000671	CcSEcCtD
Cefdinir—Convulsion—Doxorubicin—testicular cancer	0.000164	0.00067	CcSEcCtD
Cefdinir—Thrombocytopenia—Epirubicin—testicular cancer	0.000163	0.000668	CcSEcCtD
Cefdinir—Hypertension—Doxorubicin—testicular cancer	0.000163	0.000668	CcSEcCtD
Cefdinir—Insomnia—Methotrexate—testicular cancer	0.000161	0.000659	CcSEcCtD
Cefdinir—Chest pain—Doxorubicin—testicular cancer	0.000161	0.000658	CcSEcCtD
Cefdinir—Anorexia—Epirubicin—testicular cancer	0.000159	0.00065	CcSEcCtD
Cefdinir—Somnolence—Methotrexate—testicular cancer	0.000158	0.000648	CcSEcCtD
Cefdinir—Dry mouth—Doxorubicin—testicular cancer	0.000157	0.000644	CcSEcCtD
Cefdinir—Dyspepsia—Methotrexate—testicular cancer	0.000157	0.000642	CcSEcCtD
Cefdinir—Decreased appetite—Methotrexate—testicular cancer	0.000155	0.000634	CcSEcCtD
Cefdinir—Anaphylactic shock—Doxorubicin—testicular cancer	0.000154	0.000631	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000154	0.000629	CcSEcCtD
Cefdinir—Shock—Doxorubicin—testicular cancer	0.000152	0.000621	CcSEcCtD
Cefdinir—Thrombocytopenia—Doxorubicin—testicular cancer	0.000151	0.000618	CcSEcCtD
Cefdinir—Insomnia—Epirubicin—testicular cancer	0.000151	0.000617	CcSEcCtD
Cefdinir—Somnolence—Epirubicin—testicular cancer	0.000148	0.000606	CcSEcCtD
Cefdinir—Anorexia—Doxorubicin—testicular cancer	0.000147	0.000602	CcSEcCtD
Cefdinir—Dyspepsia—Epirubicin—testicular cancer	0.000147	0.0006	CcSEcCtD
Cefdinir—Gastrointestinal pain—Methotrexate—testicular cancer	0.000145	0.000596	CcSEcCtD
Cefdinir—Decreased appetite—Epirubicin—testicular cancer	0.000145	0.000593	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000144	0.000589	CcSEcCtD
Cefdinir—Constipation—Epirubicin—testicular cancer	0.000142	0.000583	CcSEcCtD
Cefdinir—Abdominal pain—Methotrexate—testicular cancer	0.000141	0.000576	CcSEcCtD
Cefdinir—Body temperature increased—Methotrexate—testicular cancer	0.000141	0.000576	CcSEcCtD
Cefdinir—Insomnia—Doxorubicin—testicular cancer	0.000139	0.000571	CcSEcCtD
Cefdinir—Somnolence—Doxorubicin—testicular cancer	0.000137	0.000561	CcSEcCtD
Cefdinir—Gastrointestinal pain—Epirubicin—testicular cancer	0.000136	0.000558	CcSEcCtD
Cefdinir—Dyspepsia—Doxorubicin—testicular cancer	0.000136	0.000556	CcSEcCtD
Cefdinir—Decreased appetite—Doxorubicin—testicular cancer	0.000134	0.000549	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000133	0.000545	CcSEcCtD
Cefdinir—Constipation—Doxorubicin—testicular cancer	0.000132	0.00054	CcSEcCtD
Cefdinir—Body temperature increased—Epirubicin—testicular cancer	0.000132	0.000539	CcSEcCtD
Cefdinir—Abdominal pain—Epirubicin—testicular cancer	0.000132	0.000539	CcSEcCtD
Cefdinir—Hypersensitivity—Methotrexate—testicular cancer	0.000131	0.000537	CcSEcCtD
Cefdinir—Asthenia—Methotrexate—testicular cancer	0.000128	0.000523	CcSEcCtD
Cefdinir—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000126	0.000516	CcSEcCtD
Cefdinir—Pruritus—Methotrexate—testicular cancer	0.000126	0.000516	CcSEcCtD
Cefdinir—Hypersensitivity—Epirubicin—testicular cancer	0.000123	0.000503	CcSEcCtD
Cefdinir—Abdominal pain—Doxorubicin—testicular cancer	0.000122	0.000499	CcSEcCtD
Cefdinir—Body temperature increased—Doxorubicin—testicular cancer	0.000122	0.000499	CcSEcCtD
Cefdinir—Diarrhoea—Methotrexate—testicular cancer	0.000122	0.000499	CcSEcCtD
Cefdinir—Asthenia—Epirubicin—testicular cancer	0.000119	0.000489	CcSEcCtD
Cefdinir—Pruritus—Epirubicin—testicular cancer	0.000118	0.000483	CcSEcCtD
Cefdinir—Dizziness—Methotrexate—testicular cancer	0.000118	0.000482	CcSEcCtD
Cefdinir—Diarrhoea—Epirubicin—testicular cancer	0.000114	0.000467	CcSEcCtD
Cefdinir—Hypersensitivity—Doxorubicin—testicular cancer	0.000113	0.000465	CcSEcCtD
Cefdinir—Vomiting—Methotrexate—testicular cancer	0.000113	0.000463	CcSEcCtD
Cefdinir—Rash—Methotrexate—testicular cancer	0.000112	0.00046	CcSEcCtD
Cefdinir—Dermatitis—Methotrexate—testicular cancer	0.000112	0.000459	CcSEcCtD
Cefdinir—Headache—Methotrexate—testicular cancer	0.000111	0.000457	CcSEcCtD
Cefdinir—Asthenia—Doxorubicin—testicular cancer	0.000111	0.000453	CcSEcCtD
Cefdinir—Dizziness—Epirubicin—testicular cancer	0.00011	0.000451	CcSEcCtD
Cefdinir—Pruritus—Doxorubicin—testicular cancer	0.000109	0.000447	CcSEcCtD
Cefdinir—Vomiting—Epirubicin—testicular cancer	0.000106	0.000434	CcSEcCtD
Cefdinir—Nausea—Methotrexate—testicular cancer	0.000106	0.000433	CcSEcCtD
Cefdinir—Diarrhoea—Doxorubicin—testicular cancer	0.000105	0.000432	CcSEcCtD
Cefdinir—Rash—Epirubicin—testicular cancer	0.000105	0.00043	CcSEcCtD
Cefdinir—Dermatitis—Epirubicin—testicular cancer	0.000105	0.00043	CcSEcCtD
Cefdinir—Headache—Epirubicin—testicular cancer	0.000104	0.000427	CcSEcCtD
Cefdinir—Dizziness—Doxorubicin—testicular cancer	0.000102	0.000417	CcSEcCtD
Cefdinir—Nausea—Epirubicin—testicular cancer	9.89e-05	0.000405	CcSEcCtD
Cefdinir—Vomiting—Doxorubicin—testicular cancer	9.79e-05	0.000401	CcSEcCtD
Cefdinir—Rash—Doxorubicin—testicular cancer	9.71e-05	0.000398	CcSEcCtD
Cefdinir—Dermatitis—Doxorubicin—testicular cancer	9.7e-05	0.000398	CcSEcCtD
Cefdinir—Headache—Doxorubicin—testicular cancer	9.65e-05	0.000395	CcSEcCtD
Cefdinir—Nausea—Doxorubicin—testicular cancer	9.15e-05	0.000375	CcSEcCtD
